Suven Life Sciences at SfN 2026

Nov 14–18, 2026 Washington, DC ~21k attendees Website

Suven Life Sciences brings 7 presentations to SfN 2026 in Washington, and exhibits at Booth 423. Its SfN 2026 program centres on drug approaches to Alzheimer’s disease, schizophrenia, mood disorders and other brain conditions. One thread explores muscarinic receptor modulators, including a study of a novel M4 modulator for Alzheimer’s disease and schizophrenia.

Organization	SfN 2026 Attendance
Suven Life Sciences Hyderabad, India
suven.com Contract research and service companies Indian company offering drug discovery and development support services, with its own central nervous system drug pipeline.	Booth Exhibiting at Booth 423 Sun, Nov 159:30am–5:00pmMon, Nov 169:30am–5:00pmTue, Nov 179:30am–5:00pmWed, Nov 189:30am–5:00pm Poster Sat Nov 14 1–5pm Part of Session PSTR004: Schizophrenia Therapeutics: Animal and Human Studies SUVN-M8036, a multimodal receptor antagonist that exhibits antipsychotic and anti-aggressive like effects in animal models WCC Halls A-C · Board N7 Poster Sat Nov 14 1–5pm Part of Session PSTR034: Cross-Disorder Variations in Cognition and Brain Architecture Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects WCC Halls A-C · Board JJ10 Poster Sat Nov 14 1–5pm Part of Session PSTR034: Cross-Disorder Variations in Cognition and Brain Architecture SUVN-L1101142, a Novel Muscarinic M4 Positive Allosteric Modulator, for the Treatment of Alzheimer’s Disease and Schizophrenia WCC Halls A-C · Board JJ11 Poster Mon Nov 16 1–5pm Part of Session PSTR192: Sleep Regulation: Anatomy, Pharmacology, Behavior Efficacy and Safety of Samelisant, an H3 Receptor Inverse Agonist, for the Treatment of Narcolepsy with or without Cataplexy: A Phase 3 Study WCC Halls A-C · Board EE18 Poster Tue Nov 17 8am–noon Part of Session PSTR222: Parkinson's Disease: Therapeutic Strategies in Preclinical Models Efficacy of SUVN-N9503012, a Selective 5-HT1A Receptor Partial Agonist, Intended for the Treatment of L-Dopa induced dyskinesia WCC Halls A-C · Board W18 Poster Tue Nov 17 8am–noon Part of Session PSTR241: Mood Disorders: Treatment and Drug Discovery Ropanicant (SUVN-911), an α4β2 nAChR Antagonist: A Phase-2b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, Evaluating the Efficacy and Safety of Ropanicant in Patients with Major Depressive Disorder WCC Halls A-C · Board II27 Poster Tue Nov 17 1–5pm Part of Session PSTR262: Alzheimer's Disease Therapeutic Strategies: Other Masupirdine (5-HT 6 Receptor Antagonist): Baseline Characteristics from a Phase 3 Study in Alzheimer’s Dementia with Agitation WCC Halls A-C · Board V22

Organization

SfN 2026 Attendance

Suven Life Sciences

Hyderabad, India

suven.com

Contract research and service companies

Indian company offering drug discovery and development support services, with its own central nervous system drug pipeline.

Booth

Exhibiting at Booth 423

Sun, Nov 159:30am–5:00pmMon, Nov 169:30am–5:00pmTue, Nov 179:30am–5:00pmWed, Nov 189:30am–5:00pm

Poster

Sat Nov 14
1–5pm

Part of Session PSTR004: Schizophrenia Therapeutics: Animal and Human Studies

SUVN-M8036, a multimodal receptor antagonist that exhibits antipsychotic and anti-aggressive like effects in animal models

WCC Halls A-C · Board N7

Poster

Sat Nov 14
1–5pm

Part of Session PSTR034: Cross-Disorder Variations in Cognition and Brain Architecture

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects

WCC Halls A-C · Board JJ10

Poster

Sat Nov 14
1–5pm

Part of Session PSTR034: Cross-Disorder Variations in Cognition and Brain Architecture

SUVN-L1101142, a Novel Muscarinic M4 Positive Allosteric Modulator, for the Treatment of Alzheimer’s Disease and Schizophrenia

WCC Halls A-C · Board JJ11

Poster

Mon Nov 16
1–5pm

Part of Session PSTR192: Sleep Regulation: Anatomy, Pharmacology, Behavior

Efficacy and Safety of Samelisant, an H3 Receptor Inverse Agonist, for the Treatment of Narcolepsy with or without Cataplexy: A Phase 3 Study

WCC Halls A-C · Board EE18

Poster

Tue Nov 17
8am–noon

Part of Session PSTR222: Parkinson's Disease: Therapeutic Strategies in Preclinical Models

Efficacy of SUVN-N9503012, a Selective 5-HT1A Receptor Partial Agonist, Intended for the Treatment of L-Dopa induced dyskinesia

WCC Halls A-C · Board W18

Poster

Tue Nov 17
8am–noon

Part of Session PSTR241: Mood Disorders: Treatment and Drug Discovery

Ropanicant (SUVN-911), an α4β2 nAChR Antagonist: A Phase-2b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, Evaluating the Efficacy and Safety of Ropanicant in Patients with Major Depressive Disorder

WCC Halls A-C · Board II27

Poster

Tue Nov 17
1–5pm

Part of Session PSTR262: Alzheimer's Disease Therapeutic Strategies: Other

Masupirdine (5-HT 6 Receptor Antagonist): Baseline Characteristics from a Phase 3 Study in Alzheimer’s Dementia with Agitation

WCC Halls A-C · Board V22

Instantly find 20 buyers from Suven Life Sciences

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with the Society for Neuroscience. Organization details are derived from SfN’s published exhibitor list, its Neuroscience Meeting Planner and each organization’s own website. Submit a correction